(Q45976200)
Statements
1 reference
Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. (English)
1 reference
Antoinette R Tan
1 reference
Eric H Rubin
1 reference
Diana C Walton
1 reference
Dale E Shuster
1 reference
Y Nancy Wong
1 reference
Fang Fang
1 reference
Simon Ashworth
1 reference
Lee S Rosen
1 reference
9 June 2009
1 reference
15
1 reference
12
1 reference
4213-4219
1 reference